• Hansa Biopharma signed a EUR 115 million licensing deal with SERB Pharmaceuticals for Idefirix in solid-organ transplant across Europe, the UK, Switzerland, Norway, Iceland, Liechtenstein, MENA.
• Received an initial EUR 110 million payment in early July.
• Will receive a further EUR 5 million once the EMA accepts the application to convert Idefirix to full marketing authorization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202607220100BITN____UKPR__SV_20260721-BIT-0802-0) on July 22, 2026, and is solely responsible for the information contained therein.